Natco Pharma Stock Surges on Affordable Drug Launch and Business Split

Natco Pharma's stock has surged, clearing a significant 13-month resistance barrier between ₹1,051-₹1,059. The breakout was backed by trading volumes nearly double the 30-day average, showing strong investor confidence. Technical indicators, including a golden crossover (50-day moving average above 200-day) and a rising Average Directional Index (ADX) at 24.93, signal strengthening bullish momentum. As of early April 2026, the company's market capitalization was approximately ₹19,400 crore.

Key Growth Drivers: Affordable Drugs and Business Split

Natco Pharma is aggressively entering the market with its Semaglutide Injection in multi-dose vials. It is the first company in India to offer this key diabetes and weight-loss treatment in vial form, directly addressing market access issues. Priced about 70% lower than pen devices and 90% less than the original brand, this strategy aims to meet a significant need among India's large patient population for diabetes and obesity. The Indian GLP-1 market is expected to grow fivefold by 2030, especially after patent expirations such as Semaglutide's in March 2026. This presents a major opportunity for companies focused on affordability and volume, aligning with an expected trend of price reductions in the Indian GLP-1 market after patents expire.

Complementing its pharmaceutical strategy, Natco Pharma's board approved spinning off its agrochemicals business into a new, wholly-owned subsidiary, Natco Crop Health Sciences Ltd., on March 24, 2026. Shareholders will receive one share in the new entity for each share they hold. This move aims to streamline operations and unlock separate value streams. This restructuring, combined with the aggressive product launch, shows a focused effort to improve operational efficiency and market standing.

Attractive Valuation Amidst Peer Comparisons

Natco Pharma trades at a Price-to-Earnings (P/E) ratio of about 12.45, significantly lower than its competitors. For comparison, Sun Pharma trades at a P/E of 33.97, Divi's Laboratories at 61.42, and Dr. Reddy's Laboratories at 17.94. This low valuation is notable considering Natco's strong stock performance of over 41.33% in the past year, supported by a reported profit growth of 41.62%. The company also boasts a strong balance sheet, with a debt-to-equity ratio of just 0.03, among the lowest in the sector. This financial health, combined with its recent stock gains, highlights a valuation gap that the current market breakout may start to close.

Mixed Analyst Views on Future Earnings

Despite positive technical signals and strategic moves, analyst sentiment for Natco Pharma is mixed. The current consensus rating is 'Neutral,' with an average 12-month price target of ₹987, suggesting a potential downside of about 4% from current levels. Some analyst reports forecast declining earnings and revenue over the next three years, predicting annual drops of -31.2% for EPS and -12.7% for revenue. This outlook contrasts with the company's recent performance and its focus on high-growth areas. However, the broader Indian pharmaceutical industry is expected to grow 9-11% in FY2026, fueled by domestic demand and exports to Europe. The US market, however, faces challenges from pricing pressures and regulatory oversight.

Potential Challenges and Analyst Caution

Natco Pharma's aggressive pricing for Semaglutide injection could boost volume, but its long-term profitability on these lower-margin products needs close watching. The regulatory environment for GLP-1 drugs is tightening, with authorities increasing oversight on sales and prescribing practices. While spinning off the agrochemicals business could unlock value, it also carries risks and uncertainties about the new company's future performance. Some analysts predict a future decline in Natco's earnings and revenue, questioning the sustainability of its current growth path. The mixed analyst ratings and price targets, which on average suggest a slight downside, indicate market caution regarding the company's immediate strategic gains versus these potential challenges. Historically, sharp price increases have sometimes led to consolidation or moderation, as seen in April 2025 when a rally above ₹840 did not prevent later price swings.